Ankylosis - 267 Studies Found Recruiting : A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation : Spondylarthritis Psoriatic Arthritis Ankylosing Spondyliti : 2016-11-28 Recruiting : A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-11-10 : Other: Placebo Drug: Bimekizumab Completed : Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study : Spondylitis, Ankylosing Recurrence : 2016-09-23 : Drug: Etanercept Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs Not yet recruiting : Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis : AS : 2016-08-29 : Drug: IBI303 12 cycles. IBI303 Active, not recruiting : Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-04-03 : Drug: BCD-085 Other: Placebo Recruiting : A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-05-03 : Biological: AIN457/Secukinumab Active, not recruiting : Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-04-04 : Biological: BCD-055 Other Name Recruiting : The Effect of NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in the Spine in Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-04-20 : Biological: Golimumab Other Na Active, not recruiting : Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-04-04 : Drug: secukinumab 150mg Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks. Recruiting : Electroacupuncture for Relieving Pain in Ankylosing Spondylitis : Ankylosing Spondylitis : 2016-02-24 : Device: Electroacupuncture <<< Previous | Next >>>